Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system–wide patient blood management program
- 3 July 2017
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 57 (9) , 2189-2196
Abstract
BACKGROUND: Little is published on patient blood management (PBM) programs in hematology. In 2008 Western Australia announced a health system–wide PBM program with PBM staff appointments commencing in November 2009. Our aim was to assess the impact this program had on blood utilization and patient outcomes in intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation.STUDY DESIGN AND METHODS: A retrospective study of 695 admissions at two tertiary hospitals receiving intensive chemotherapy for acute leukemia or undergoing hematopoietic stem cell transplantation between July 2010 and December 2014 was conducted. Main outcomes included pre–red blood cell (RBC) transfusion hemoglobin (Hb) levels, single‐unit RBC transfusions, number of RBC and platelet (PLT) units transfused per admission, subsequent day case transfusions, length of stay, serious bleeding, and in‐hospital mortality.RESULTS: Over the study period, the mean RBC units transfused per admission decreased 39% from 6.1 to 3.7 (p < 0.001), and the mean PLT units transfused decreased 35% from 6.3 to 4.1 (p < 0.001), with mean RBC and PLT units transfused for follow‐up day cases decreasing from 0.6 to 0.4 units (p < 0.001). Mean pre‐RBC transfusion Hb level decreased from 8.0 to 6.8 g/dL (p < 0.001), and single‐unit RBC transfusions increased 39% to 67% (p < 0.001). This reduction represents blood product cost savings of AU$694,886 (US$654,007). There were no significant changes in unadjusted or adjusted length of stay, serious bleeding events, or in‐hospital mortality over the study.CONCLUSION: The health system–wide PBM program had a significant impact, reducing blood product use and costs without increased morbidity or mortality in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation.Keywords
This publication has 36 references indexed in Scilit:
- Improved outcomes and reduced costs associated with a health‐system–wide patient blood management program: a retrospective observational study in four major adult tertiary‐care hospitalsTransfusion, 2017
- Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United StatesTransfusion, 2016
- A Programmatic Approach to Patient Blood Management – Reducing Transfusions and Improving Patient OutcomesThe Open Anesthesiology Journal, 2015
- Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemiaAnnals of Hematology, 2015
- Increased hospital costs associated with red blood cell transfusionTransfusion, 2014
- Economic considerations on transfusion medicine and patient blood managementBest Practice & Research Clinical Anaesthesiology, 2013
- Drivers for change: Western Australia Patient Blood Management Program (WA PBMP), World Health Assembly (WHA) and Advisory Committee on Blood Safety and Availability (ACBSA)Best Practice & Research Clinical Anaesthesiology, 2013
- Appropriateness of Allogeneic Red Blood Cell Transfusion: The International Consensus Conference on Transfusion OutcomesTransfusion Medicine Reviews, 2011
- Patient blood management: a growing challenge and opportunityTransfusion, 2011
- Adverse Blood Transfusion Outcomes: Establishing CausationTransfusion Medicine Reviews, 2011